A	B	C
1	Main
2		Brand	Padcev
3		Generic	enfortumab vedotin
4		MOA	Nectin-4 ADC
5		Indication	Urothelial carcinoma
6		Economics	SGEN, 4503
7		Clinical Trials
8			Phase Ib/2 KEYNOTE-869/EV-103 1L UC - NCT03288545
9			Priority review for BLA